Parabilis Medicines, Inc.

PBLS Nasdaq SEC CIK 1657677
Follow Parabilis Medicines Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $2.1M
Net income −$44.5M −32.9% vs same quarter last year
EPS, diluted −$0.36 +98.3% vs same quarter last year
Operating cash flow −$41.1M −30.3% vs same quarter last year
Revenue by quarter
$0
$0
$148K
$2.1M
Q2 25 Q3 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing